Ono Pharmaceutical Co., Ltd. (OPHLY) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Osaka, 日本. 現CEOは Gyo Sagara.
OPHLY を有する IPO日 2012-10-02, 3,853 名の正社員, に上場 Other OTC, 時価総額 $7.32B.
Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company headquartered in Osaka with a history dating back to 1717. The company develops, manufactures, and markets a diverse portfolio of prescription medications across oncology, cardiovascular, immunology, and other therapeutic areas, with leading products including OPDIVO for cancer treatment, FORXIGA for diabetes, ORENCIA for rheumatoid arthritis, and CORALAN for heart failure. Operating globally through its subsidiaries, Ono maintains a robust pipeline of drugs in development targeting a wide range of cancers, neurological disorders, autoimmune conditions, and other serious diseases. The company combines its heritage in pharmaceutical innovation with modern research capabilities to serve patients and healthcare systems worldwide.
